Unicycive Therapeutics (NASDAQ:UNCY) Stock Falls 1.3% – Time to Sell?

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) traded down 1.3% on Friday. The stock traded as low as $3.71 and last traded at $3.89. Approximately 1,212,401 shares traded hands during mid-day trading, an increase of 15% from the average session volume of 1,055,401 shares. The stock had previously closed at $3.94.

More Unicycive Therapeutics News

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: The FDA accepted Unicycive’s resubmitted New Drug Application for oxylanthanum carbonate, a potential phosphate binder for patients with chronic kidney disease on dialysis. The resubmission includes Chemistry, Manufacturing, and Controls data from a new drug-product manufacturing vendor. The FDA assigned a March 25, 2027 PDUFA action date, providing a defined regulatory catalyst, although acceptance does not guarantee approval. FDA acceptance and PDUFA date article
• Positive Sentiment: The average analyst price target reportedly increased 12.32% to $32.54, suggesting substantial potential upside relative to recent trading levels. However, price targets can change quickly and may reflect limited analyst coverage for the clinical-stage biotechnology company. Analyst price target article
• Neutral Sentiment: Multiple law firms reminded investors of a November 2, 2026 lead-plaintiff deadline in a pending securities class action covering purchases from December 29, 2025 through June 29, 2026. The notices largely repeat the same litigation information rather than represent new operating developments. Class-action deadline notice
• Negative Sentiment: The lawsuit alleges Unicycive failed to disclose that it had not inspected or audited its third-party manufacturer’s facility for current Good Manufacturing Practice compliance before an earlier NDA resubmission. Plaintiffs claim this exposed investors to another Complete Response Letter and contributed to a reported 39.1% stock decline. The allegations have not been proven, but the litigation creates legal costs, reputational risk, and uncertainty around the company’s manufacturing readiness. Securities lawsuit allegations

Analyst Upgrades and Downgrades

UNCY has been the subject of a number of research reports. B. Riley Financial reaffirmed a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Guggenheim reissued a “buy” rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Finally, Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 19th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $18.25.

Unicycive Therapeutics Stock Down 1.3%

The firm has a market capitalization of $108.36 million, a PE ratio of -2.22 and a beta of 1.83. The company’s 50-day simple moving average is $4.72 and its 200 day simple moving average is $5.96.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.41. On average, sell-side analysts forecast that Unicycive Therapeutics, Inc. will post -1.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Unicycive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP purchased a new stake in shares of Unicycive Therapeutics during the first quarter worth about $940,000. Seven Fleet Capital Management LP purchased a new position in shares of Unicycive Therapeutics in the first quarter worth $367,000. Bank of New York Mellon Corp acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $248,000. Bank of America Corp DE grew its holdings in shares of Unicycive Therapeutics by 19,327.6% during the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after buying an additional 29,378 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Unicycive Therapeutics during the first quarter valued at $161,000. 40.42% of the stock is owned by hedge funds and other institutional investors.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.